Next Article in Journal
Epigenetic Mechanisms and Therapeutic Perspectives for Neurodevelopmental Disorders
Next Article in Special Issue
Inactivation of Caliciviruses
Previous Article in Journal
Oral Administration of Shark Type II Collagen Suppresses Complete Freund’s Adjuvant-Induced Rheumatoid Arthritis in Rats
Previous Article in Special Issue
89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
Open AccessReview

On the Regulatory Approval Pathway of Biosimilar Products

by Jun Wang 1,* and Shein-Chung Chow 2
1
Duke University School of Medicine, DUMC 3813, Durham, NC 27710, USA
2
Duke University School of Medicine, Duke Box 2721, Durham, NC 27710, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2012, 5(4), 353-368; https://doi.org/10.3390/ph5040353
Received: 20 February 2012 / Revised: 20 March 2012 / Accepted: 28 March 2012 / Published: 30 March 2012
(This article belongs to the Special Issue Biologics)
Biosimilars (or follow-on biologics) are a new class of medicine which enters the market subsequent to a previously approved version. They have demonstrated similarity to innovator biologic products in terms of quality, safety, and efficacy. The EMA has taken the lead in the regulatory approval framework for biosimilar products, and WHO has published guidelines on the evaluation of biosimilars in order to facilitate the global harmonization. Based on EMA and WHO guidelines, many other countries such as Canada, Japan and Korea have also issued their own guidance for evaluating follow-on biologics. The US FDA was authorized to approve follow-on biologics by the BPCI Act passed by the US Congress on March 23, 2010, and has just issued a draft guidance in early 2012. The basic concepts and main principles of approving biosimilars are similar among various nations, notwithstanding some differences in regard to the scope, the choice of reference product, and the data requirement. This article reviews the regulatory approval pathway of biosimilar products in different regions. View Full-Text
Keywords: biosimilars; biosimilarity; interchangeability; WHO; EMA; FDA biosimilars; biosimilarity; interchangeability; WHO; EMA; FDA
MDPI and ACS Style

Wang, J.; Chow, S.-C. On the Regulatory Approval Pathway of Biosimilar Products. Pharmaceuticals 2012, 5, 353-368.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop